65 completed, 4 unknown, 4 withdrawn, 3 terminated. 18 Phase 2, 13 Phase 4, 8 Phase 3, 2 Not applicable, 2 Phase 1.
Follow this drug Literature Review of Interferon beta-1b trials Research Report on Interferon beta-1b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited) - Multiple Sclerosis (MS) | Active not recruiting | Bayer | 4 | 2024-03-20 | 2026-07-06 | |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector Interferon-beta-1b (BETASERON, BAY 86-5046) - Multiple Sclerosis | Completed | Bayer | 100 | 2020-11-24 | 2023-07-24 | |
| IFN-beta 1b and Remdesivir for COVID19 Interferon beta-1b, Remdesivir - Covid19 | Phase 2 | Unknown | The University of Hong Kong | 100 | 2020-11-20 | 2020-12-10 |
| IFN Beta-1b and Ribavirin for Covid-19 Interferon beta-1b, Ribavirin - Covid19 | Phase 2 | Unknown | The University of Hong Kong | 96 | 2020-07-29 | 2020-07-31 |
| Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19 Interferon beta-1b, Clofazimine - COVID-19 | Phase 2 | Unknown | The University of Hong Kong | 81 | 2020-07-14 | 2020-07-15 |
| An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19 | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 60 | 2020-04-09 | 2020-05-05 |
| Double Therapy With IFN-beta 1b and Hydroxychloroquine Interferon Beta-1B, Hydroxychloroquine - COVID | Phase 2 | Completed | The University of Hong Kong | 60 | 2020-04-09 | 2020-07-28 |
| Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B - Novel Coronavirus Infection | Phase 2 | Completed | The University of Hong Kong | 127 | 2020-02-10 | 2020-04-15 |
| PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon myBETAapp, PEAK, Betaferon, BAY86-5046 - Multiple Sclerosis | Completed | Bayer | 79 | 2019-02-20 | 2021-08-25 | |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
| A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b - Multiple Sclerosis, Relapsing-Remitting | Completed | Biogen | 626 | 2017-11-27 | 2019-09-25 | |
| Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp - Multiple Sclerosis | Completed | Bayer | 96 | 2017-09-15 | 2019-03-26 | |
| Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy peginterferon beta-1a, interferon beta-1a, interferon beta-1b - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Biogen | 80 | 2017-01-30 | 2020-11-25 |
| MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b Combination of Lopinavir /Ritonavir and Interferon beta-1b, Placebo - Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Phase 2 / Phase 3 | Completed | King Abdullah International Medical Research Center | 95 | 2016-07-01 | 2020-05-20 |
| EPID Multiple Sclerosis Pregnancy Study Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd - Multiple Sclerosis | Completed | Bayer | 2089 | 2016-05-02 | 2019-08-14 | |
| Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device - Multiple Sclerosis, Relapsing-Remitting | Completed | Bayer | 146 | 2016-02-05 | 2018-09-06 | |
| Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect Autoinjector - Multiple Sclerosis | Completed | Bayer | 162 | 2015-09-08 | 2023-07-24 | |
| Comparison Study of PF530 and Betaferon in Healthy Subjects Interferon beta-1b (PF530, Betaferon) - Multiple Sclerosis | Phase 1 | Completed | Pfenex, Inc | 12 | 2015-03-01 | 2015-11-16 |
Showing 20 of 78. Sign in to see all of them.
Multiple Sclerosis (47) · Multiple Sclerosis, Relapsing-Remitting (26) · COVID-19 (5) · Multiple Sclerosis, Chronic Progressive (4) · Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Carcinoma in Situ (2) · Fatigue (2) · Motor Activity (2) · Recurrence (2) · AIDS-Related Complex (1) · AIDS-Related Opportunistic Infections (1) · Adenoviridae Infections (1) · Bone Diseases, Metabolic (1) · Cardiomyopathies (1)
Bayer (44) · The University of Hong Kong (5) · Biogen (4) · Novartis Pharmaceuticals (3) · Sanofi (3) · Claudio Gobbi (2) · Clinique de sclérose en plaques et neuromusculaire de l'Outaouais (1) · EMD Serono (1) · EMD Serono Research & Development Institute, Inc. (1) · Hoffmann-La Roche (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · King Abdullah International Medical Research Center (1) · Melinda Magyari (1) · Nancy Hammond, MD (1)
United States (24) · Germany (21) · Canada (14) · France (14) · Italy (14) · Spain (11) · Austria (9) · Belgium (9) · Israel (9) · Sweden (9) · Switzerland (9) · Netherlands (8) · Poland (8) · Czechia (7) · Finland (7)
Ivan FN Hung, MD FRCP (5) · Claudio Gobbi, Dr med. (1) · Claudio Gobbi, MD (1) · Daniel Ontaneda, MD, MSc (1) · Ellen M. Mowry, MD, MCR (1) · Fernando Dangond, MD (1) · Helene Brooks (1) · Howard Zwibel, MD (1) · Hubert C Chen, MD (1)
PMID 22622860, PMID 32401715, PMID 17679016, PMID 17846268, PMID 18004635, PMID 19279320, PMID 19457248, PMID 19687024, PMID 19729344, PMID 19748319, PMID 19879194, PMID 19901165, PMID 20003436, PMID 20530324, PMID 20562430, PMID 20621365, PMID 21061396, PMID 21636099, PMID 21795647, PMID 21849647, PMID 21952094, PMID 22140424, PMID 22183938, PMID 22193561, PMID 22541587, PMID 22615737, PMID 23216674, PMID 23647445, PMID 23842212, PMID 23851964, PMID 23915113, PMID 24011220, PMID 24576156, PMID 24624979, PMID 25424122, PMID 25787057, PMID 25877635, PMID 26265273, PMID 26265274, PMID 27090116, PMID 27653529, PMID 28607708, PMID 28724581, PMID 28877664, PMID 29382391, PMID 30027104, PMID 30143019, PMID 31359863, PMID 31900204, PMID 32445440
2008 (2), 2005 (1), 2009 (1), 2014 (1), 2016 (1), 2019 (1)